{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:54:50Z","timestamp":1794408890166,"version":"4.9.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Research Grants Council of the Hong Kong Special Administrative Region","award":["CUHK 14108921"],"award-info":[{"award-number":["CUHK 14108921"]}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82402076"],"award-info":[{"award-number":["82402076"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Overseas Distinguished Scholars Program of Guangdong Pharmaceutical University","award":["GDPUODS2025013"],"award-info":[{"award-number":["GDPUODS2025013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Anaplastic thyroid carcinoma (ATC) is one of the most aggressive endocrine malignancies, characterized by rapid progression, extensive metastasis, and extremely poor prognosis. Despite advances in molecular oncology, the mechanisms driving ATC metastasis and therapeutic resistance remain largely unclear. Cancer cells that detach from the extracellular matrix must evade a specific form of apoptosis known as anoikis, and the ability to survive under these anchorage-independent conditions is a critical prerequisite for metastatic dissemination. The transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) has emerged as a master regulator of oxidative-stress responses and tumor adaptation, yet its function in governing anoikis resistance in ATC is not well understood. Here we demonstrate that Nrf2 expression is markedly upregulated in ATC tissues and cell lines, where its nuclear translocation drives transcriptional activation of anti-apoptotic and redox-protective genes including\n                    <jats:italic>BCL-2 and SLC7A11<\/jats:italic>\n                    . Under detachment stress, Nrf2 activation enhances cell viability, inhibits apoptosis, and facilitates multicellular aggregate formation, thereby promoting survival. Conversely, genetic silencing or pharmacological inhibition of Nrf2 with Brusatol markedly suppresses proliferation, invasion, and\n                    <jats:italic>in vivo<\/jats:italic>\n                    liver metastasis. Collectively, these findings identify Nrf2 as a pivotal driver of ATC anoikis resistance and metastatic competence through regulation of the BCL-2\/SLC7A11 axis. Targeting the Nrf2-dependent survival pathway may thus offer a promising therapeutic strategy for this otherwise refractory malignancy.\n                  <\/jats:p>","DOI":"10.1186\/s43556-025-00355-7","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T06:35:01Z","timestamp":1762756501000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The role of Nrf2 in anoikis resistance and metastasis in anaplastic thyroid carcinoma"],"prefix":"10.1186","volume":"6","author":[{"given":"Simiao","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huangcan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongqin","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhai","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-shan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlei","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Andrew","family":"van Hasselt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason YK","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Chi Fai","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7276-3830","authenticated-orcid":false,"given":"George Gong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"1","key":"355_CR1","doi-asserted-by":"publisher","first-page":"12345","DOI":"10.3390\/cancers15010172","volume":"15","author":"J Luo","year":"2022","unstructured":"Luo J, Wang Y, Zhao L, Wang C, Zhang Z. Anti-anaplastic thyroid cancer (ATC) effects and mechanisms of PLX3397 (pexidartinib), a multi-targeted tyrosine kinase inhibitor (TKI). Cancers (Basel). 2022;15(1):12345. https:\/\/doi.org\/10.3390\/cancers15010172.","journal-title":"Cancers (Basel)"},{"key":"355_CR2","unstructured":"National Cancer Institute, The SEER Cancer Statistics program. https:\/\/seer.cancer.gov\/statistics-network\/. Accessed 26 Feb 2025."},{"key":"355_CR3","doi-asserted-by":"publisher","unstructured":"Perrier ND, Brierley JD, Tuttle RM. Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2018;68(1):55-63.https:\/\/doi.org\/10.3322\/caac.21439","DOI":"10.3322\/caac.21439"},{"issue":"3","key":"355_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/thy.2020.0944","volume":"31","author":"KC Bible","year":"2021","unstructured":"Bible KC, Kebebew E, Brierley J, Brito JP, Cabanillas ME, Clark TJ Jr, et al. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid. 2021;31(3):337\u201386. https:\/\/doi.org\/10.1089\/thy.2020.0944.","journal-title":"Thyroid"},{"key":"355_CR5","doi-asserted-by":"publisher","unstructured":"Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Oncol. 2019;30(12):1856-83.https:\/\/doi.org\/10.1093\/annonc\/mdz400","DOI":"10.1093\/annonc\/mdz400"},{"key":"355_CR6","doi-asserted-by":"publisher","unstructured":"Lee JS, Lee JS, Yun HJ, Chang H, Kim SM, Lee YS, et al. Prognosis of Anaplastic Thyroid Cancer with Distant Metastasis. Cancers (Basel). 2022;14(23):98765.https:\/\/doi.org\/10.3390\/cancers14235784","DOI":"10.3390\/cancers14235784"},{"issue":"13","key":"355_CR7","doi-asserted-by":"publisher","first-page":"5432","DOI":"10.3390\/ijms21134777","volume":"21","author":"F He","year":"2020","unstructured":"He F, Ru X, Wen T. NRF2, a transcription factor for stress response and beyond. Int J Mol Sci. 2020;21(13):5432. https:\/\/doi.org\/10.3390\/ijms21134777.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"355_CR8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1164\/rccm.201004-0457ED","volume":"182","author":"RC Reddy","year":"2010","unstructured":"Reddy RC, Standiford TJ. Nrf2 and PPAR\u03b3. Am J Respir Crit Care Med. 2010;182(2):134\u20135. https:\/\/doi.org\/10.1164\/rccm.201004-0457ED.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"355_CR9","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.cell.2019.06.003","volume":"178","author":"L Lignitto","year":"2019","unstructured":"Lignitto L, LeBoeuf SE, Homer H, Jiang S, Askenazi M, Karakousi TR, et al. Nrf2 Activation Promotes Lung Cancer Metastasis by Inhibiting the Degradation of Bach1. Cell. 2019;178(2):316-29 e18. https:\/\/doi.org\/10.1016\/j.cell.2019.06.003.","journal-title":"Cell."},{"issue":"45","key":"355_CR10","doi-asserted-by":"publisher","first-page":"73593","DOI":"10.18632\/oncotarget.12435","volume":"7","author":"C Zhang","year":"2016","unstructured":"Zhang C, Wang HJ, Bao QC, Wang L, Guo TK, Chen WL, et al. NRF2 promotes breast cancer cell proliferation and metastasis by increasing RhoA\/ROCK pathway signal transduction. Oncotarget. 2016;7(45):73593\u2013606. https:\/\/doi.org\/10.18632\/oncotarget.12435.","journal-title":"Oncotarget"},{"issue":"1","key":"355_CR11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s12967-023-04287-0","volume":"21","author":"M Zhang","year":"2023","unstructured":"Zhang M, Hong X, Ma N, Wei Z, Ci X, Zhang S. The promoting effect and mechanism of Nrf2 on cell metastasis in cervical cancer. J Transl Med. 2023;21(1):433. https:\/\/doi.org\/10.1186\/s12967-023-04287-0.","journal-title":"J Transl Med"},{"issue":"1","key":"355_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3390\/antiox13010070","volume":"13","author":"C Glorieux","year":"2024","unstructured":"Glorieux C, Enr\u00edquez C, Gonz\u00e1lez C, Aguirre-Mart\u00ednez G, Buc Calderon P. The multifaceted roles of NRF2 in cancer: friend or foe? Antioxidants. 2024;13(1):70.","journal-title":"Antioxidants"},{"issue":"5","key":"355_CR13","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.ccell.2021.02.016","volume":"39","author":"H Su","year":"2021","unstructured":"Su H, Yang F, Fu R, Li X, French R, Mose E, et al. Cancer cells escape autophagy inhibition via NRF2-induced macropinocytosis. Cancer Cell. 2021;39(5):678-93 e11. https:\/\/doi.org\/10.1016\/j.ccell.2021.02.016.","journal-title":"Cancer Cell."},{"issue":"4","key":"355_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.tibs.2014.02.002","volume":"39","author":"JD Hayes","year":"2014","unstructured":"Hayes JD, Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci. 2014;39(4):199\u2013218. https:\/\/doi.org\/10.1016\/j.tibs.2014.02.002.","journal-title":"Trends Biochem Sci"},{"key":"355_CR15","doi-asserted-by":"publisher","first-page":"3900330","DOI":"10.1155\/2021\/3900330","volume":"2021","author":"Z Gong","year":"2021","unstructured":"Gong Z, Xue L, Wei M, Liu Z, Vlantis AC, van Hasselt CA, et al. The knockdown of Nrf2 suppressed tumor growth and increased the sensitivity to lenvatinib in anaplastic thyroid cancer. Oxid Med Cell Longev. 2021;2021:3900330. https:\/\/doi.org\/10.1155\/2021\/3900330.","journal-title":"Oxid Med Cell Longev"},{"issue":"12","key":"355_CR16","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1016\/j.bbamcr.2013.06.026","volume":"1833","author":"P Paoli","year":"2013","unstructured":"Paoli P, Giannoni E, Chiarugi P. Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta. 2013;1833(12):3481\u201398. https:\/\/doi.org\/10.1016\/j.bbamcr.2013.06.026.","journal-title":"Biochim Biophys Acta"},{"key":"355_CR17","doi-asserted-by":"publisher","first-page":"306879","DOI":"10.1155\/2012\/306879","volume":"2012","author":"YN Kim","year":"2012","unstructured":"Kim YN, Koo KH, Sung JY, Yun UJ, Kim H. Anoikis resistance: an essential prerequisite for tumor metastasis. Int J Cell Biol. 2012;2012:306879. https:\/\/doi.org\/10.1155\/2012\/306879.","journal-title":"Int J Cell Biol"},{"key":"355_CR18","doi-asserted-by":"publisher","first-page":"626577","DOI":"10.3389\/fonc.2021.626577","volume":"11","author":"FO Adeshakin","year":"2021","unstructured":"Adeshakin FO, Adeshakin AO, Afolabi LO, Yan D, Zhang G, Wan X. Mechanisms for modulating anoikis resistance in cancer and the relevance of metabolic reprogramming. Front Oncol. 2021;11:626577. https:\/\/doi.org\/10.3389\/fonc.2021.626577.","journal-title":"Front Oncol"},{"issue":"7","key":"355_CR19","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1158\/1541-7786.MCR-19-1057","volume":"18","author":"BT Sawyer","year":"2020","unstructured":"Sawyer BT, Qamar L, Yamamoto TM, McMellen A, Watson ZL, Richer JK, et al. Targeting fatty acid oxidation to promote anoikis and inhibit ovarian cancer progression. Mol Cancer Res. 2020;18(7):1088\u201398. https:\/\/doi.org\/10.1158\/1541-7786.MCR-19-1057.","journal-title":"Mol Cancer Res"},{"issue":"6","key":"355_CR20","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/bjc.2012.302","volume":"107","author":"G Dom","year":"2012","unstructured":"Dom G, Tarabichi M, Unger K, Thomas G, Oczko-Wojciechowska M, Bogdanova T, et al. A gene expression signature distinguishes normal tissues of sporadic and radiation-induced papillary thyroid carcinomas. Br J Cancer. 2012;107(6):994\u20131000. https:\/\/doi.org\/10.1038\/bjc.2012.302.","journal-title":"Br J Cancer"},{"issue":"22","key":"355_CR21","doi-asserted-by":"publisher","first-page":"10983","DOI":"10.1158\/0008-5472.CAN-06-2298","volume":"66","author":"XJ Wang","year":"2006","unstructured":"Wang XJ, Hayes JD, Wolf CR. Generation of a stable antioxidant response element-driven reporter gene cell line and its use to show redox-dependent activation of nrf2 by cancer chemotherapeutic agents. Cancer Res. 2006;66(22):10983\u201394. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-2298.","journal-title":"Cancer Res"},{"issue":"9","key":"355_CR22","doi-asserted-by":"publisher","first-page":"5231","DOI":"10.7314\/apjcp.2013.14.9.5231","volume":"14","author":"XF Hu","year":"2013","unstructured":"Hu XF, Yao J, Gao SG, Wang XS, Peng XQ, Yang YT, et al. Nrf2 overexpression predicts prognosis and 5-FU resistance in gastric cancer. Asian Pac J Cancer Prev. 2013;14(9):5231\u20135. https:\/\/doi.org\/10.7314\/apjcp.2013.14.9.5231.","journal-title":"Asian Pac J Cancer Prev"},{"key":"355_CR23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/1476-4598-9-206","volume":"9","author":"P Kumar","year":"2010","unstructured":"Kumar P, Yadav A, Patel SN, Islam M, Pan Q, Merajver SD, et al. Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis. Mol Cancer. 2010;9:206. https:\/\/doi.org\/10.1186\/1476-4598-9-206.","journal-title":"Mol Cancer"},{"key":"355_CR24","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.phrs.2014.10.004","volume":"91","author":"E Bhakkiyalakshmi","year":"2015","unstructured":"Bhakkiyalakshmi E, Sireesh D, Rajaguru P, Paulmurugan R, Ramkumar KM. The emerging role of redox-sensitive Nrf2-Keap1 pathway in diabetes. Pharmacol Res. 2015;91:104\u201314. https:\/\/doi.org\/10.1016\/j.phrs.2014.10.004.","journal-title":"Pharmacol Res"},{"key":"355_CR25","doi-asserted-by":"publisher","first-page":"102389","DOI":"10.1016\/j.redox.2022.102389","volume":"54","author":"S Liu","year":"2022","unstructured":"Liu S, Pi J, Zhang Q. Signal amplification in the KEAP1-NRF2-ARE antioxidant response pathway. Redox Biol. 2022;54:102389. https:\/\/doi.org\/10.1016\/j.redox.2022.102389.","journal-title":"Redox Biol"},{"issue":"19","key":"355_CR26","doi-asserted-by":"publisher","first-page":"9433","DOI":"10.1073\/pnas.1821323116","volume":"116","author":"JKM Lim","year":"2019","unstructured":"Lim JKM, Delaidelli A, Minaker SW, Zhang HF, Colovic M, Yang H, et al. Cystine\/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance. Proc Natl Acad Sci USA. 2019;116(19):9433\u201342. https:\/\/doi.org\/10.1073\/pnas.1821323116.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"355_CR27","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1038\/s41467-024-46857-w","volume":"15","author":"Z Wang","year":"2024","unstructured":"Wang Z, Yang X, Chen D, Liu Y, Li Z, Duan S, et al. GAS41 modulates ferroptosis by anchoring NRF2 on chromatin. Nat Commun. 2024;15(1):2531. https:\/\/doi.org\/10.1038\/s41467-024-46857-w.","journal-title":"Nat Commun"},{"issue":"1","key":"355_CR28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s12967-021-03042-7","volume":"19","author":"L Feng","year":"2021","unstructured":"Feng L, Zhao K, Sun L, Yin X, Zhang J, Liu C, et al. SLC7A11 regulated by NRF2 modulates esophageal squamous cell carcinoma radiosensitivity by inhibiting ferroptosis. J Transl Med. 2021;19(1):367. https:\/\/doi.org\/10.1186\/s12967-021-03042-7.","journal-title":"J Transl Med"},{"issue":"1","key":"355_CR29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.molcel.2017.09.009","volume":"68","author":"D Chen","year":"2017","unstructured":"Chen D, Tavana O, Chu B, Erber L, Chen Y, Baer R, et al. NRF2 Is a Major Target of ARF in p53-Independent Tumor Suppression. Mol Cell. 2017;68(1):224-32 e4. https:\/\/doi.org\/10.1016\/j.molcel.2017.09.009.","journal-title":"Mol Cell."},{"key":"355_CR30","doi-asserted-by":"publisher","unstructured":"Gong Z, Xue L, Vlantis AC, van Hasselt CA, Chan JYK, Fang J, et al. Brusatol attenuated proliferation and invasion induced by KRAS in differentiated thyroid cancer through inhibiting Nrf2. J Endocrinol Invest. 2024;47(5):1271-80.https:\/\/doi.org\/10.1007\/s40618-023-02248-4","DOI":"10.1007\/s40618-023-02248-4"},{"issue":"10","key":"355_CR31","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","volume":"72","author":"IA Prior","year":"2012","unstructured":"Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72(10):2457\u201367. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-2612.","journal-title":"Cancer Res"},{"issue":"1","key":"355_CR32","doi-asserted-by":"publisher","first-page":"101678","DOI":"10.1016\/j.beem.2022.101678","volume":"37","author":"SN Rao","year":"2023","unstructured":"Rao SN, Smallridge RC. Anaplastic thyroid cancer: an update. Best Pract Res Clin Endocrinol Metab. 2023;37(1):101678. https:\/\/doi.org\/10.1016\/j.beem.2022.101678.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"355_CR33","doi-asserted-by":"publisher","unstructured":"Maniakas A, Zafereo M, Cabanillas ME. Anaplastic Thyroid Cancer: New Horizons and Challenges. Endocrinol Metab Clin North Am. 2022;51(2):391-401.https:\/\/doi.org\/10.1016\/j.ecl.2021.11.020","DOI":"10.1016\/j.ecl.2021.11.020"},{"key":"355_CR34","doi-asserted-by":"publisher","unstructured":"Jannin A, Escande A, Al Ghuzlan A, Blanchard P, Hartl D, Chevalier B, et al. Anaplastic Thyroid Carcinoma: An Update. Cancers (Basel). 2022;14(4).https:\/\/doi.org\/10.3390\/cancers14041061","DOI":"10.3390\/cancers14041061"},{"issue":"3","key":"355_CR35","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/cncy.22519","volume":"130","author":"A Silver Karcioglu","year":"2022","unstructured":"Silver Karcioglu A, Iwata AJ, Pusztaszeri M, Abdelhamid Ahmed AH, Randolph GW. The American Thyroid Association (ATA) integrates molecular testing into its framework for managing patients with anaplastic thyroid carcinoma (ATC): update on the 2021 ATA ATC guidelines. Cancer Cytopathol. 2022;130(3):174\u201380. https:\/\/doi.org\/10.1002\/cncy.22519.","journal-title":"Cancer Cytopathol"},{"key":"355_CR36","doi-asserted-by":"publisher","first-page":"101099","DOI":"10.1016\/j.drup.2024.101099","volume":"75","author":"Y Wang","year":"2024","unstructured":"Wang Y, Cheng S, Fleishman JS, Chen J, Tang H, Chen ZS, et al. Targeting anoikis resistance as a strategy for cancer therapy. Drug Resist Updat. 2024;75:101099. https:\/\/doi.org\/10.1016\/j.drup.2024.101099.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"355_CR37","doi-asserted-by":"publisher","first-page":"12044","DOI":"10.1038\/s41598-024-62978-0","volume":"14","author":"J Li","year":"2024","unstructured":"Li J, Cao Q, Tong M. Deciphering anoikis resistance and identifying prognostic biomarkers in clear cell renal cell carcinoma epithelial cells. Sci Rep. 2024;14(1):12044. https:\/\/doi.org\/10.1038\/s41598-024-62978-0.","journal-title":"Sci Rep"},{"issue":"8","key":"355_CR38","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1097\/CAD.0000000000001616","volume":"35","author":"S Gulia","year":"2024","unstructured":"Gulia S, Chandra P, Das A. Combating anoikis resistance: bioactive compounds transforming prostate cancer therapy. Anticancer Drugs. 2024;35(8):687\u201397. https:\/\/doi.org\/10.1097\/CAD.0000000000001616.","journal-title":"Anticancer Drugs"},{"issue":"9\u201310","key":"355_CR39","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1007\/s10495-024-01994-x","volume":"29","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Chen X, Li Y, Zhang F, Quan Z, Wang Z, et al. The resistance to anoikis, mediated by Spp1, and the evasion of immune surveillance facilitate the invasion and metastasis of hepatocellular carcinoma. Apoptosis. 2024;29(9\u201310):1564\u201383. https:\/\/doi.org\/10.1007\/s10495-024-01994-x.","journal-title":"Apoptosis"},{"issue":"17","key":"355_CR40","doi-asserted-by":"publisher","first-page":"7545","DOI":"10.7150\/thno.46001","volume":"10","author":"G Ye","year":"2020","unstructured":"Ye G, Yang Q, Lei X, Zhu X, Li F, He J, et al. Nuclear MYH9-induced CTNNB1 transcription, targeted by staurosporin, promotes gastric cancer cell anoikis resistance and metastasis. Theranostics. 2020;10(17):7545\u201360. https:\/\/doi.org\/10.7150\/thno.46001.","journal-title":"Theranostics"},{"issue":"1","key":"355_CR41","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s13046-022-02381-7","volume":"41","author":"Y Yu","year":"2022","unstructured":"Yu Y, Song Y, Cheng L, Chen L, Liu B, Lu D, et al. CircCEMIP promotes anoikis-resistance by enhancing protective autophagy in prostate cancer cells. J Exp Clin Cancer Res. 2022;41(1):188. https:\/\/doi.org\/10.1186\/s13046-022-02381-7.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"355_CR42","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/ki.2013.248","volume":"84","author":"LM Shelton","year":"2013","unstructured":"Shelton LM, Park BK, Copple IM. Role of Nrf2 in protection against acute kidney injury. Kidney Int. 2013;84(6):1090\u20135. https:\/\/doi.org\/10.1038\/ki.2013.248.","journal-title":"Kidney Int"},{"key":"355_CR43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.freeradbiomed.2020.03.023","volume":"157","author":"A Kopacz","year":"2020","unstructured":"Kopacz A, Kloska D, Forman HJ, Jozkowicz A, Grochot-Przeczek A. Beyond repression of Nrf2: an update on Keap1. Free Radic Biol Med. 2020;157:63\u201374. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2020.03.023.","journal-title":"Free Radic Biol Med"},{"key":"355_CR44","doi-asserted-by":"publisher","unstructured":"Tossetta G, Fantone S, Montanari E, Marzioni D, Goteri G. Role of NRF2 in Ovarian Cancer. Antioxidants (Basel). 2022;11(4).https:\/\/doi.org\/10.3390\/antiox11040663.","DOI":"10.3390\/antiox11040663"},{"issue":"1","key":"355_CR45","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/s41598-021-81021-0","volume":"11","author":"E Ko","year":"2021","unstructured":"Ko E, Kim D, Min DW, Kwon SH, Lee JY. Nrf2 regulates cell motility through RhoA-ROCK1 signalling in non-small-cell lung cancer cells. Sci Rep. 2021;11(1):1247. https:\/\/doi.org\/10.1038\/s41598-021-81021-0.","journal-title":"Sci Rep"},{"key":"355_CR46","doi-asserted-by":"publisher","unstructured":"Zhao G, Liu Y, Wei X, Yang C, Lu J, Yan S, et al. Identification of Penexanthone A as a Novel Chemosensitizer to Induce Ferroptosis by Targeting Nrf2 in Human Colorectal Cancer Cells. Mar Drugs. 2024;22(8). https:\/\/doi.org\/10.3390\/md22080357.","DOI":"10.3390\/md22080357"},{"key":"355_CR47","doi-asserted-by":"publisher","first-page":"116324","DOI":"10.1016\/j.biopha.2024.116324","volume":"173","author":"Z Gong","year":"2024","unstructured":"Gong Z, Xue L, Li H, Fan S, van Hasselt CA, Li D, et al. Targeting Nrf2 to treat thyroid cancer. Biomed Pharmacother. 2024;173:116324. https:\/\/doi.org\/10.1016\/j.biopha.2024.116324.","journal-title":"Biomed Pharmacother"},{"issue":"41","key":"355_CR48","doi-asserted-by":"publisher","first-page":"69847","DOI":"10.18632\/oncotarget.19349","volume":"8","author":"A Namani","year":"2017","unstructured":"Namani A, Cui QQ, Wu Y, Wang H, Wang XJ, Tang X. NRF2-regulated metabolic gene signature as a prognostic biomarker in non-small cell lung cancer. Oncotarget. 2017;8(41):69847\u201362. https:\/\/doi.org\/10.18632\/oncotarget.19349.","journal-title":"Oncotarget"},{"issue":"6","key":"355_CR49","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3892\/etm.2022.11321","volume":"23","author":"B Liu","year":"2022","unstructured":"Liu B, Wang H. Oxaliplatin induces ferroptosis and oxidative stress in HT29 colorectal cancer cells by inhibiting the Nrf2 signaling pathway. Exp Ther Med. 2022;23(6):394. https:\/\/doi.org\/10.3892\/etm.2022.11321.","journal-title":"Exp Ther Med"},{"issue":"13","key":"355_CR50","doi-asserted-by":"publisher","first-page":"9873","DOI":"10.1074\/jbc.M111.312694","volume":"287","author":"SK Niture","year":"2012","unstructured":"Niture SK, Jaiswal AK. Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J Biol Chem. 2012;287(13):9873\u201386. https:\/\/doi.org\/10.1074\/jbc.M111.312694.","journal-title":"J Biol Chem"},{"issue":"5","key":"355_CR51","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.bbamcr.2008.01.002","volume":"1783","author":"GH Liu","year":"2008","unstructured":"Liu GH, Qu J, Shen X. NF-kappaB\/p65 antagonizes Nrf2-ARE pathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK. Biochim Biophys Acta. 2008;1783(5):713\u201327. https:\/\/doi.org\/10.1016\/j.bbamcr.2008.01.002.","journal-title":"Biochim Biophys Acta"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-025-00355-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-025-00355-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-025-00355-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:19:36Z","timestamp":1762881576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-025-00355-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["355"],"URL":"https:\/\/doi.org\/10.1186\/s43556-025-00355-7","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involving human participants was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the Third Affiliated Hospital of Harbin Medical University (Approval No. XJS2022-39). Written informed consent was obtained from all patients prior to sample collection.All animal procedures were conducted following institutional ethical guidelines and were approved by the Animal Ethics Committee of The Chinese University of Hong Kong (Approval No. (23-1317) in DH\/HT&A\/8\/2\/1 Pt.57).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}